Примери за използване на Reactions occurred на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Grade 3 infusion reactions occurred in 1% of patients.
In patients receiving ADCETRIS combination therapy,serious adverse reactions occurred in 36% of patients.
Serious adverse reactions occurred in 56% of patients.
In that situation, the doctor may ask the patient to keep a record of the contents of each meal and whether reactions occurred that are consistent with allergy.
Neurologic adverse reactions occurred in 67% of patients.
The reactions occurred within minutes after taking asfotase alfa, and can occur in patients who were taking asfotase alfa for more than one year.
Serious anaphylactic reactions occurred in 3.5% of the patients.
These reactions occurred within several days and up to several months after initiating Xeloda therapy and, in a few cases, within one month after stopping Xeloda.
Serious adverse drug reactions occurred in 12% of patients.
These reactions occurred around the time of infusion, were transient and were rarely treatment limiting.
Two of these 3 anaphylactoid reactions occurred in patients with Crohn's disease.
Serious reactions occurred in 3% of patients including cases of pyrexia, urticaria, atrial fibrillation, nausea, chest discomfort, and hypotension.
In all patients, infusion-associated reactions occurred primarily during the first infusion.
Allergic reactions occurred on initial or subsequent treatment in patients receiving filgrastim.
Of the cases that reported time to onset,most severe liver reactions occurred within one month of the start of treatment.
Some of these reactions occurred after the first administration of Simponi.
Of the cases that reported time to onset,most severe liver reactions occurred within one month of start of treatment.
Some of these reactions occurred after the first administration of golimumab.
The following clinically significant,immune-related adverse reactions occurred at an incidence of less than 1% of 591 patients treated with cemiplimab.
Adverse reactions occurred within 3 days following vaccination except fever which appears within 14 days after the injection.
The majority of serious infusion reactions occurred during the second infusion at week 2.
Most of these reactions occurred during the second reinduction infusion at Week 2.
Most cases of allergic reactions occurred in patients under 12 years of age.
Nearly all reactions occurred during infusion or within 4 hours of completing an infusion.
Hypersensitivity reactions and allergic reactions occurred in some cases after the first administration of ciprofloxacin.
Almost all reactions occurred during the infusion or within 4 hours of completion of the infusion.
All anaphylactic reactions occurred during the first olaratumab infusion.
Gastrointestinal adverse reactions occurred more frequently during the dose escalation phase of the study and decreased once patients established the maximum tolerated dose of lomitapide.
Liver-related adverse reactions occurred in 42.8% of nintedanib-treated patients.
Where Grade 3 or 4 reactions occurred, the actual total frequency and the frequency of Grade 3 or 4 reactions are given.